Schering Corporation

Merck Sharp + Dohme Corp.

Other

Canji Inc.

Joseph A Hedrick

Albert Zlotnik

Thomas M Laz

Suke Wang

Shelby P Umland

Kelley L Morse

Jiang X Behan

Alain Vicari

Janine M Morales

Frederick J Monsma

Wei W Wang

Jean E Lachowicz

Bernhard Homey

Monica Zepeda

Frederick James Monsma, Jr

Alain P Vicari

Susan A Hudak

Eric L Gustafson

Robert A Kastelein

J Fernando Bazan

Donna M Rennick

Diane Hollenbaugh

Nicholas J Murgolo

Theodore R Sana

Tatyana Churakova

Qing Zhang

The present invention provides, in part, methods and compositions for treating lipid disorders comprising administering a polypeptide that inhibits PCSK9. A novel method for identifying polypeptides that interact with PCSK9 is also provided.

Method of reducing total cholesterol level by administering matrilin-2 polypeptide

The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.

Anti-PCSK9 and methods for treating lipid and cholesterol disorders

Novel CC chemokines from human, reagents related thereto including purified proteins, specific antibodies and nucleic acids encoding these chemokines are provided. Also provided are methods of making and using said reagents and diagnostic kits.

Nucleic acids encoding CCL27

Anti-CCL27 antibodies

The present invention provides an isolated mammalian histamine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by histamine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian histamine receptor.

Histamine receptor

The present invention provides an isolated mammalian adenosine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by adenosine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian adenosine receptor.

Adenosine receptor

Novel chemokines and 7 transmembrane receptors from mammals, reagents related thereto, including purified proteins, specific antibodies, and nucleic acids encoding the chemokines and receptors are disclosed. Methods of using the chemokines, receptors, reagents and diagnostic kits are also provided.

DNAXCCR10

Nucleic acids encoding mammalian, e.g., rodent, IL-1&#x3b4;, IL-1&#x3b5;, purified IL-1&#x3b4; and IL-1&#x3b5; proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

Mammalian cytokines; related reagents and methods

Histamine receptor antibody

CCL27 polypeptides

7 transmembrane receptor family member BLRX

The present invention relates to the agonist properties of vMIP-I for the chemokine receptor CCR8 as expressed on Th2 cells. Methods of modulating a physiological signal specific to Th2 cells comprising contacting these cells with vMIP-I, agonists and antagonists thereof are disclosed. Methods for treating disease using CCR8 antagonists are also provided. The modulation of the Th2 cell populations through the vMIP-I/CCR8 interaction provides a new means for diagnosing and treating specific disease states and immunologic conditions.

Modulating Th2 cell levels via vMIP-I/CCR8 interaction

This invention relates to the use of lymphotactin or lymphotactin antagonists for administration to an animal. The administration of these therapeutic entities will attract certain cell types, or can be blocked to prevent such attraction. It also provides means to protect stem cells.

Lymphotactin uses

Growing community of inventors

South River, NJ, United States of America

Joseph A Hedrick